VC-backed VenatoRx beefs up team with three new hires
Malvern, Pennsylvania-based VenatoRx, a pharmaceutical company focused on developing novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections, has expanded its team with three new additions. Jennifer Ellis is now senior vice president of quality; Dr. Paul McGovern is vice president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital.
21 August 2019•5 mins read
